Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.

被引：6
|
作者：
Apolo, Andrea B. [1 ]
Girardi, da Motta Daniel [1 ]
Niglio, Scot Anthony [1 ]
Nadal, Rosa Maria [2 ]
Cordes, Lisa M. [2 ]
Steinberg, Seth M. [3 ]
Costello, Rene
Trepel, Jane B. [4 ]
Lee, Sunmin
Lee, Min-Jung [5 ]
Cao Liang [6 ]
Gulley, James L. [1 ]
Bottaro, Donald P. [7 ]
Saraiya, Biren [8 ,9 ]
Pal, Sumanta K. [10 ]
Quinn, David, I [11 ]
Lara, Primo Lucky N. [12 ]
Parnes, Howard L. [1 ]
Dahut, William L. [13 ]
Mortazavi, Amir [14 ]
机构：
[1] NCI, NIH, Bethesda, MD 20892 USA
[2] NIH, Bldg 10, Bethesda, MD 20892 USA
[3] NCI, Biostat & Data Management Sect, NIH, Bethesda, MD 20892 USA
[4] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[5] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[6] NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA
[7] Ctr Canc Res, Div Canc Treatment & Diag, Bethesda, MD USA
[8] Rutgers Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ USA
[9] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA
[10] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA
[11] USC Norris Canc Hosp, Los Angeles, CA USA
[12] Univ Calif, Sacramento, CA USA
[13] NCI, Bethesda, MD 20892 USA
[14] Ohio State Univ, Wexner Med Ctr, Arthur G James Canc Hosp, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Infante, Jeffrey R.
    Rini, Brian I.
    McDermott, David F.
    Ernstoff, Marc
    Voss, Martin Henner
    Sharma, Padmanee
    Pal, Sumanta Kumar
    Razak, Albiruni R. A.
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Spratlin, Jennifer L.
    Shen, Yun
    Gagnier, Paul
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Expanded cohort results from CheckMate 016: a Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Lnfante, Jeffrey R.
    Rini, Brian I.
    Mcdermott, David F.
    Ernstoff, Marc S.
    Voss, Martin H.
    Sharma, Padmanee
    Pal, Sumanta K.
    Razak, Albiruni
    Kollmannsberger, Christian
    Heng, Daniel Y. C.
    Spratlin, Jennifer
    Shen, Yun
    Gagnier, Paul
    Amin, Asim
    BJU INTERNATIONAL, 2015, 116 : 11 - 11
  • [23] Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.
    Dizon, Don S.
    Mathews, Cara Amanda
    David, Shannon MacLaughlan
    Machan, Jason T.
    Hadfield, Matthew James
    Marks, Eric, I
    Bansal, Rani
    McGinn, Christine
    Hassinger, Faith
    Luppe, Denise
    Grigelevich, Janine
    Mitchell, Kelly A.
    Braga, Adam
    Sturtevant, Ashlee
    Wood, Roxanne
    Matulonis, Ursula A.
    Wright, Alexi A.
    Campos, Susana M.
    Birrer, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA5500 - LBA5500
  • [24] Final results fronts the phase I study expansion cohort of Dehio0932, an oral HSP90 inhibitor, in patients with solid tumors.
    Fumoleau, Pierre
    Soria, Jean-Charles
    Delord, Jean-Pierre
    Belli, Riccardo
    Brienza, Silvan
    Zanna, Claudio
    Destaillats, Alice
    Rouits, Elisabeth
    Hollebecque, Antoine
    Gazzah, Anas
    Isambert, Nicolas
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO
    Lorenzen, S.
    Thuss-Patience, P. C.
    Folprecht, G.
    Knorrenschild, J. Riera
    Heinemann, V.
    Goekkurt, E.
    Dechow, T. N.
    Ettrich, T. J.
    Luley, K. B.
    Moulin, J. C.
    Lindig, U.
    Angermeier, S.
    Waidmann, O.
    Pink, D.
    Bolling, C.
    Junge, S.
    Pauligk, C.
    Gaiser, T.
    Goetze, T. O.
    Al-Batran, S. E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1099 - S1099
  • [26] The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results from phase I trial in Japanese patients with metastatic solid tumors.
    Nishina, T.
    Hirashima, T.
    Sugio, K.
    Muro, K.
    Akinaga, S.
    Maeda, H.
    Takahashi, T.
    Naito, T.
    Murakami, H.
    Yasui, H.
    Boku, N.
    Yamamoto, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
    Hu, Xichun
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Wu, Junyan
    Wang, Ying
    Hao, Yanrong
    Ge, Junyou
    Qing, Yan
    Yi, Shuli
    Yang, Qixian
    Rao, Huajing
    Yuan, Juanjuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Rini, B. I.
    McDermott, D.
    Lewis, L.
    Voss, M. H.
    Sharma, P.
    Pal, S. K.
    Razak, A.
    Kollmannsberger, C. K.
    Heng, D.
    Spratlin, J.
    McHenry, B.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL).
    Rajdev, Lakshmi
    Chiao, Elizabeth Y.
    Lensing, Shelly
    Little, Richard F.
    Dittmer, Dirk
    Einstein, Mark H.
    Haigentz, Missak
    Sparano, Joseph A.
    Mitsuyasu, Ronald T.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.
    Callahan, Margaret K.
    Bendell, Johanna C.
    Chan, Emily
    Morse, Michael
    Pillai, Rathi Narayana
    Bono, Petri
    Jaeger, Dirk
    Evans, T. R. Jeffry
    Chau, Ian
    Calvo, Emillano
    Le, Dung T.
    Ott, Patrick Alexander
    Taylor, Matthew Hiram
    Sharma, Padmanoo
    Antonia, Scott Joseph
    Sharkey, Brian
    Christensen, Olaf
    Amin, Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345